Drug Pricing: Page 3

  • Vials of Eisai and Biogen's new Alzheimer's drug Leqembi
    Image attribution tooltip
    Courtesy of Eisai
    Image attribution tooltip
    New Alzheimer's drugs

    Eisai, in pricing new Alzheimer’s drug, tries to sidestep controversy

    The pharma set the average annual cost of it and Biogen’s newly approved medicine Leqembi to $26,500, below the cost of the companies’ earlier drug Aduhelm but above one estimate of cost effectiveness.

    By Jan. 6, 2023
  • Pharma companies boost drug prices to start year, but hikes lag inflation

    Analysts noted hundreds of list price increases, including dozens by Pfizer. Many checked in around 5%, roughly in line with hikes taken in recent years.

    By Jan. 3, 2023
  • Trendline


    The arrival of lookalike competition to AbbVie’s Humira in the U.S. presents an opportunity, and a test, for the cost-saving potential of biosimilars.

    By BioPharma Dive staff
  • A Bluebird bio employee works at a laboratory.
    Image attribution tooltip
    Permission granted by Bluebird bio
    Image attribution tooltip

    Gene therapy approval won, Bluebird takes on next challenge: selling it

    The biotech is still waiting to treat its first commercial patient with Zynteglo, but says it has not seen insurers deny coverage for the beta thalassemia drug.

    By Dec. 12, 2022
  • Three scientists in lab coats look at something at a work table.
    Image attribution tooltip
    Hinterhaus Productions via Getty Images
    Image attribution tooltip
    Sponsored by First Republic Bank

    Life science investment outlook: thinking beyond the pandemic

    Learn about the investment landscape for life science companies, heading into 2023.

    Dec. 12, 2022
  • A picture from chest-up of Bernie Sanders speaking to reporters. The top of the US capitol building is visible behind him.
    Image attribution tooltip
    Anna Moneymaker/Getty Images via Getty Images
    Image attribution tooltip

    Sanders poised to lead Senate health committee

    The longtime pharma critic is set to become chair of the HELP Committee, a post that holds significant power in directing congressional efforts on healthcare issues.

    By Susan Kelly • Nov. 28, 2022
  • FDA approves Rezvoglar as second ‘interchangeable’ insulin biosimilar

    Eli Lilly’s long-acting copycat drug, first approved in late 2021, now has a designation that will allow pharmacists to swap it for Sanofi’s Lantus.

    By Nov. 18, 2022
  • Xavier Becerra sits on a couch onstage at HLTH.
    Image attribution tooltip
    Rebecca Pifer/BioPharma Dive
    Image attribution tooltip

    Divided Congress after midterms will allow HHS to execute on policy priorities, Becerra says

    The agency is focused on implementing drug price negotiation in Medicare and surprise billing regulations, according to the secretary.

    By Rebecca Pifer • Nov. 16, 2022
  • Alexis Borisy and Melanie Nallicheri of EQRx, at launch
    Image attribution tooltip
    Courtesy of EQRx
    Image attribution tooltip

    EQRx redraws ‘radical’ drug pricing plans for first two drugs

    The buzzy startup, which planned to undercut big pharma on price, also dropped plans to seek U.S. approval in lung cancer of an immunotherapy competitor to Keytruda.

    By Nov. 10, 2022
  • Prescriptions drugs on a production line.
    Image attribution tooltip
    zorazhuang via Getty Images
    Image attribution tooltip

    Pharma earnings outline drug law’s looming impact on sales, development

    While companies remain unsure of the Inflation Reduction Act's effects, some began to warn investors about the likelihood of lower sales and reduced profits.

    By Nov. 9, 2022
  • Inflation word on calculator in idea for FED consider interest rate hike
    Image attribution tooltip


    Image attribution tooltip
    Sponsored by GoodRx

    Inflation Reduction Act: What are the healthcare implications?

    The Inflation Reduction Act helps support American families by lowering prescription drug prices and reducing overall healthcare costs.

    Oct. 31, 2022
  • Sponsored by GoodRx

    Worried about provider consolidation? Learn about GoodRx engagement solutions

    GoodRx has developed strong relationships with both patients and providers over the past decade and is helping pharmaceutical manufacturers address the changes resulting from this trend.

    Oct. 10, 2022
  • A photograph of a box of Amylyx Pharmaceuticals' ALS medicine Relyvrio
    Image attribution tooltip
    Permission granted by Amylyx Pharmaceuticals
    Image attribution tooltip
    ALS drug development

    Amylyx sets ALS drug price at $158,000 per year, opening new debate on cost

    The list price is slightly lower than another ALS therapy approved five years ago, but well above what one drug cost watchdog believes to be reasonable, given its purported benefit.

    By Sept. 30, 2022
  • Image attribution tooltip
    Image attribution tooltip

    Novartis warns of sales hit after federal court turns back patent appeal

    The Swiss company is evaluating “all available options” following the ruling, which could lead to the launch of copycat versions of its MS drug Gilenya.

    By Kristin Jensen • Sept. 21, 2022
  • Image attribution tooltip
    Jeff J Mitchell via Getty Images
    Image attribution tooltip
    Deep Dive

    Can biosimilars, after years of limited impact, finally make a mark in the US?

    Seven years after the first copycat biologic drug arrived in the U.S., expected cost savings have been modest at best. The next few years will show whether the knockoff drugs can live up to their cut-price promise.

    By Sept. 7, 2022
  • A headshot of Akili CEO Eddie Martucci
    Image attribution tooltip
    Permission granted by Akili Inc.
    Image attribution tooltip

    Akili CEO Martucci sees ‘massive’ need for company’s ADHD video-game treatment

    With enough cash now to last two years, the company, which merged with a SPAC last week, hopes it can change the way children with ADHD are treated.

    By Elise Reuter • Aug. 29, 2022
  • Workers gather inside BioMarin’s gene therapy manufacturing plant in Novato, California.
    Image attribution tooltip
    Courtesy of BioMarin Pharmaceutical
    Image attribution tooltip

    With European approval secured, BioMarin puts roughly $1.5M price tag on hemophilia gene therapy

    On a conference call, BioMarin executives revealed the anticipated price for Roctavian and the company's initial launch plans, which include pay-for-performance deals customized to different markets.

    By Aug. 25, 2022
  • A Bluebird bio employee works at a laboratory.
    Image attribution tooltip
    Permission granted by Bluebird bio
    Image attribution tooltip

    With $2.8M gene therapy, Bluebird sets new bar for US drug pricing

    Approved for severe beta thalassemia, Zynteglo will test insurers’ willingness to pay for expensive one-time treatments. Its market launch is likely to be watched carefully by other gene therapy developers.

    By Aug. 18, 2022
  • Nancy Pelosi sits at a table to sign the inflation reduction act. She's surrounded by people clapping.
    Image attribution tooltip
    Drew Angerer/Getty Images via Getty Images
    Image attribution tooltip

    Pharma industry braces as drug pricing bill passes Congress

    The Inflation Reduction Act, signed into law by President Biden in August, was one of the most significant political defeats for the industry in years, and will reshape companies’ business plans moving forward. 

    By Aug. 15, 2022
  • senator Chuck Schumer pauses under an arch in the United States Senate. Both of his hands are raised and giving a 'thumbs up'
    Image attribution tooltip
    Drew Angerer/Getty Images via Getty Images
    Image attribution tooltip

    Senate passage of drug pricing bill brings major defeat closer for pharma industry

    The legislation, which would allow Medicare to negotiate prices on up to 60 drugs by 2029, passed on a party-line vote and now goes to the House, where it is expected to pass.

    By Aug. 8, 2022
  • A view of the Capitol Dome from below with an American flag waving in the wind on the left side and blue skies in the background.
    Image attribution tooltip
    iStock via Getty Images
    Image attribution tooltip

    Pharma CEOs press case against drug price negotiation as bill gains support

    On earnings calls with investors, executives reiterated opposition to legislation advanced by Democrats that would curtail their pricing power in the U.S.

    By Aug. 4, 2022
  • Rendered illustration of human DNA
    Image attribution tooltip
    DKosig via Getty Images
    Image attribution tooltip

    Roche digs deeper into gene therapy for the eye

    The Swiss drugmaker, which already owns rights to a marketed gene therapy for inherited vision loss, will work with startup Avista Therapeutics to develop better delivery tools for the complex treatments. 

    By July 20, 2022
  • UnitedHealth Group's headquarters building in Minnetonka, Minnesota.
    Image attribution tooltip
    UnitedHealth Group
    Image attribution tooltip

    UnitedHealth to offer some drugs, including insulin, at no cost share in 2023

    The initiative aims to address inflationary pressures and prevent worse health outcomes down the line, CEO Andrew Witty told investors Friday.

    By Rebecca Pifer • July 15, 2022
  • Image attribution tooltip
    Justin Sullivan via Getty Images
    Image attribution tooltip

    California to manufacture its own insulin, governor says

    Gov. Gavin Newsom announced a $100 million budget to create a production facility and to develop affordable insulin products, saying the medicines’ high cost “epitomizes market failures.”

    By Susan Kelly • July 11, 2022
  • Image attribution tooltip
    Elizabeth Regan / Industry Dive
    Image attribution tooltip

    Watchdog group cautious on Amylyx’s ALS drug benefits, potential cost

    ICER, an influential nonprofit, suggested in a draft report that Amylyx’s closely watched ALS treatment would not be cost effective if priced on par with a currently available treatment.

    By Updated June 14, 2022
  • Image attribution tooltip
    Image attribution tooltip

    Roche SMA drug approved in youngest infants, challenging Novartis and Biogen

    Evrysdi, the only oral drug for the neurodegenerative disorder, can now be used to treat babies younger than 2 months who have been identified through newborn screening.

    By May 31, 2022